

APPENDIX 3Z – T. JUSTUS HOMBURG

Please note that the attached Appendix 3Z does not correspond with the previous Director's Interest Notice, being the Appendix 3Y announced on 15 February 2008. A total of 30,000 unlisted options held by Mr Homburg expired on 8 November 2008.

The Company did not lodge an Appendix 3Y in response to this change.

The Company has reviewed its disclosure arrangements with directors in light of this omission, and is satisfied that such situations will be avoided in the future.

Yours faithfully,



Paul Dixon
Company Secretary

About Progen

Progen Pharmaceuticals Limited is a biotechnology company committed to the discovery, development and commercialization of small molecule pharmaceuticals primarily for the treatment of cancer. Progen has built a focus and strength in anti-cancer drug discovery and development. Progen targets the multiple mechanisms of cancer across its three technology platforms of angiogenesis, epigenetics and cell proliferation. Progen has operations in Australia and the United States of America.
www.progen-pharma.com

For more information:

Paul Dixon
Company Secretary
+61 7 3842 3333

Appendix 3Z

Final Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity PROGEN PHARMACEUTICALS LIMITED
ABN 82 010 975 612

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	T. JUSTUS HOMBURG
Date of last notice	15 February 2008
Date that director ceased to be director	1 July 2009

Part 1 – Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities 52,778 Ordinary, fully paid shares 500,000 unlisted employee stock options 1,389 quoted stock options
--

+ See chapter 19 for defined terms.

Appendix 3Z

Final Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest	Number & class of securities
N/A	Nil

Part 3 – Director's interests in contracts

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	N/A

+ See chapter 19 for defined terms.